DR. REDDY S LABORATORIES (500124) — Latest Corporate Announcements
₹1,237
+₹7.60 (+0.62%)
Market Cap
₹1,03,040.69 Cr
P/E Ratio
31.13
52W Range
₹1101 – ₹1414.9
Board Meeting Intimations
📅 Scheduled Board Meeting & Agenda
Meeting Date: 23-Oct-2026
Agenda / Purpose: Financial Results
Timeline: In 10 days
Corporate Actions & Regulatory Filings
To consider and approve the financial results for the period ended September 30, 2026
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dr Reddys Laboratories Ltd - 500124 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Dr Reddys Laboratories Ltd - 500124 - Closure of Trading Window
Dr Reddys Laboratories Ltd - 500124 - Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ending September 30, 2026.
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Dr Reddys Laboratories Ltd - 500124 - Clarification sought from Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
To consider the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ending on June 30, 2026
To consider and approve the financial results for the period ended March 31, 2026
To consider and approve the financial results for the period ended December 31, 2025
To consider and approve the financial results for the period ended September 30, 2025
To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters
To consider and approve the financial results for the period ended December 31, 2024
To consider and approve the financial results for the period ended September 30, 2024
Financial Results (Quarterly & Annual)
| Quarter / Period | Meeting / Outcome Date | Status | Filing Details |
|---|---|---|---|
| Quarter Ended 30-Sep-2026 (Q2 FY27) | 23-Oct-2026 | Scheduled Upcoming | To consider and approve the financial results for the period ended September 30, 2026 |
| Quarter Ended 30-Jun-2026 (Q1 FY27) (STD & CONSOL) | 22-Jul-2026 | Declared | To consider the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ending on June 30, 2026 |
| Year Ended 31-Mar-2026 (Q4 FY26) | 12-May-2026 | Declared | To consider and approve the financial results for the period ended March 31, 2026 |
| Quarter Ended 31-Dec-2025 (Q3 FY26) | 21-Jan-2026 | Declared | To consider and approve the financial results for the period ended December 31, 2025 |
| Quarter Ended 30-Sep-2025 (Q2 FY26) | 24-Oct-2025 | Declared | To consider and approve the financial results for the period ended September 30, 2025 |
| Year Ended 31-Mar-2025 (Q4 FY25) | 09-May-2025 | Declared | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters |
| Quarter Ended 31-Dec-2024 (Q3 FY25) | 23-Jan-2025 | Declared | To consider and approve the financial results for the period ended December 31, 2024 |
| Quarter Ended 30-Sep-2024 (Q2 FY25) | 05-Nov-2024 | Declared | To consider and approve the financial results for the period ended September 30, 2024 |
| Quarter Ended 30-Jun-2024 (Q1 FY25) | 27-Jul-2024 | Declared | To consider and approve the Unaudited financial results for the quarter ending June 30, 2024 |
| Year Ended 31-Mar-2024 (Q4 FY24) (STD & CONSOL) | 07-May-2024 | Declared | To consider and approve the Audited Standalone and Consolidated financial results for quarter and financial year ending on March 31, 2024, and to recommend dividend, if any, for the financial year 2023-24 |
| Quarter Ended 31-Dec-2023 (Q3 FY24) | 30-Jan-2024 | Declared | To consider and approve the unaudited financial results for the quarter and nine months ending December 31, 2023 |
| Quarter Ended 30-Sep-2023 (Q2 FY24) | 27-Oct-2023 | Declared | To consider and approve the unaudited financial results for the quarter and half year ending September 30, 2023 |
Track Related Peer Equities
Related Research Guides & Regulatory Playbooks
Frequently Asked Questions about DR. REDDY S LABORATORIES BSE Disclosures
What is the latest BSE announcement by DR. REDDY S LABORATORIES?
The latest BSE disclosure by DR. REDDY S LABORATORIES (DRREDDY), filed on 23-Oct-2026 , is: "To consider and approve the financial results for the period ended September 30, 2026". Bsenexus tracks every official filing for DR. REDDY S LABORATORIES with AI-powered summaries on its announcements feed.
When is DR. REDDY S LABORATORIES's next board meeting?
DR. REDDY S LABORATORIES has a board meeting scheduled for 23-Oct-2026 (in 10 days) to consider: Financial Results.
When does DR. REDDY S LABORATORIES declare quarterly results?
Under SEBI (LODR) Regulation 33, listed companies submit quarterly unaudited results within 45 days of the quarter ending, and annual audited figures within 60 days. DR. REDDY S LABORATORIES's recent results history is tabulated above. Track scheduled board meetings on the Bsenexus Results Calendar.